Figures and References
Transcription
Figures and References
Delayed-type hypersensitivity (DTH), cytotoxicity Humoral immunity Influence of immunological factors including cytokines T-cell-mediated autoimmunity, graft rejection Allergy, antibody-mediated autoimmune diseases, tolerance Th1 cell Th2 cell Figure .. A Model to Illustrate the Complex Balance between T helper 1(Th1) and Th2 Cells Harber, M., Sundstedt, A., and Wraith, D. (2000). The Role of Cytokines in Immunological Tolerance: Potential for Therapy. Expert Reviews in Molecular Medicine, 2(9), 1–20. © Cambridge Journals, reproduced with permission. REFERENCES Bamias, G., Martin, C., & Marini, M. (2003). Expression, localization and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol, 171, 4868–4874. Bartel, G., Weiss, I., Turetschek, K., et al. (2008). Ingested matter affects intestinal lesions in Crohn’s disease. Inflamm Bowel Dis, 14, 374–382. Baumgart, D. C., & Sandborn, W. J. (2007). Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 369, 1641–1657. Belluzi, A., Brignola, C., Campieri, M., Pera, A., Boschi, S., & Miglioli, M. (1996). Effect of an enterical-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med, 334, 1557–1560. Blumenthal M. editor. (2003). The ABC Clinical Guide to Herbs. 1st ed. Texas, American Botanical Council. Borreul, N., Carol, M., & Casellas, F. (2002). Increased mucosal turnout necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut, 51, 659–64. Braegger, C. R., Nicholls, S., & Murch, S. H. (1992). Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 339, 89–91. Buddington, R. K., & Weiher, E. (1999). The application of ecological principles and fermentable fibers to manage the gastrointestinal tract ecosystem. Journal of Nutrition, 129, 1446S–1450S. Buning, C., Geerdts, L., Fiedler, T., et al. (2006). DLG5 variants in inflammatory bowel disease. Am J Gastroenterol, 101, 786–792. Camacho-Barquero, L., Villegas, I., Sanchez-Calvo, J. M., et al. (2007). Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol, 7(3), 333–342. Chamaillard, M., Iacob, R., Desreumaux, P., & Colombel, J. (2006). Advances and perspectives in the genetics of inflammatory bowel diseases. Clin Gastroenterol Hepatol, 4, 143–51. Cho, Judy. (2006). Genetic advances in inflammatory bowel disease. Curr Treat Options Gastroenterol, 9, 191–200. Cottone, M., Rosselli, M., Orlando, A. (1994). Smoking habits and recurrence in Crohn’s disease. Gastroenterology, 106, 643–48. Crohn’s and Colitis Foundation of America. (2007). What is Crohn’s Disease? Retrieved November 8, 2007, from http://www.ccfa.org/info/about/crohns Croucher, P. J., Mascheretti, S., & Hampe, J. (2003). Haplotype structure and association to Crohn’s disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet, 11, 6–16. Ding, S., Minohara, Y., Fan, X. J., et al. (2007). Helicobacter pylori infection induces oxidative stress and programmed cell death in human gastric epithelial cells. Infect Immun, 75, 4030–4039. Duggan, C., Ganno, J., & Walker, W. A. (2002) Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr, 75, 789–808. Erdman, S., Fox, J. G., & Dangler, C. A. (2001). Typhiocolitis in NF-kappa B-deficient mice. Journal of Immunology, 166, 1443–1447. Faber, S. (2001). The treatment of abnormal gut flora improves symptoms in IBS patients using IBS-QOL. American College of Gastroenterology 66th Annual Scientific Meeting, May 28, 2001, Abstract 750369. Ferguson, L., Shelling, A. N., Browning, B. L., Huebner, C., & Petermann, I. (2007) Genes, diet and inflammatory bowel disease. Mutat Res, 622, 70–83. Ferguson, L. R., Shelling, A. N., Lauren, D., et al. (2007). Nutrigenomics and gut health. Mutat Res, 622, 1–6. Fisher, S. A., Hampe, J., Onnie, C. M., et al. (2006). Direct or indirect association in a complex disease: the role of SLC22A4 and SLC22A5 functional variants in Crohn disease. Hum Mutat, 27, 778–785. Fogg-Johnson, N., & Kaput, J. (2003) Nutrigenomics: an emerging scientific discipline. Food Technol, 57, 60–67. Galland, L. (2008) Gastroinstintal Dysregulation: Connections to Chronic Disease. Gig Harbor, Institute for Functional Medicine. Gasche, C., Scholmerich, J., & Brynskov, J. (2000). A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna (1998). Inflamm Bowel Dis, 6, 8–15. Gautam, S. C., Gao, X., & Dulchavsky, S. (2007). Immunomodulation by curcumin. Adv Exp Med Biol, 595, 321–341. Genova Diagnostics. (2007). Retrieved November 10, 2007 from http://www.gdx.net/ home/ Gerhardt, H., Seifert, F., Buvari, P., et al. (2001). Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol, 39(1), 11–17. Gestel, G., Besancon, P., & Rouanet, J. M. (1994). Comparative evaluation of the effects of two different forms of dietary fibre (rice bran vs. wheat bran) on rat colonic mucosa and faecal microflora. Ann Nutr Metab, 38, 249–256. Girardin, S. E., Boneca, I. G., & Viala, J. (2003). Nod2 is a general sensor of peptidoglycan through muramyl depeptide (MDP) detection. J Biol Chem, 278, 8869–8872. Griffin, S., Alderson, D., & Farndon, J. (1989). Acid resistant lipase replacement therapy in chronic exocrine insufficiency: a study in dogs. Gut, 30, 1012–1015. Go, V. L., Nguyen, C. T., Harris, D. M., & Lee, W. N. (2005). Nutrient-gene interaction: metabolic genotype-phenotype relationship. J Nutr, 135, 3016S–3020S. Gupta, I., Parihar, A., Malhotra, P., et al. (2001) Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Medica, 67(5), 391–395. Gupta I, Parihar A, Malhotra P, et al. (1997) Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res, 2(1), 37–43. Halfvarson, J., Bresso, F., D’Amato, M., Jarnerot, G., Pettersson, S., & Tysk, C. (2005). CARD15/NOD2 polymorphisms do not explain concordance of Crohn’s disease in Swedish monozygotic twins. Dig Liver Dis, 37, 768–772. Hampe, J., Cuthbert, A., Croucher, P. J., et al. (2001). Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet, 357, 1925–1928. Han, P. D., Burke, A., Baldassano, R. N., Rombeau, J. L., & Lichtenstein, G. R. (1999). Nutrition and inflammatory bowel disease. Gastroenterology Clinics of North America, 28, 423–443. Hanai, H., Iida, T., Takeuchi, K., et al. (2006). Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol, 4(12), 1502–1506. Head, K. (2004). Inflammatory bowel disease part II: Crohn’s disease—pathophysiology and conventional and alternative treatment options. Altern Med Rev, 9, 360–401. Huemer, R editor. (1986) The Roots of Molecular Medicine: A Tribute To Linus Pauling. New York, W. H. Freeman. Hollander, D. (1988). Crohn’s disease: a permeability disorder of the tight-junction? Gut, 29, 1621–1624. Hollander, D. (1993). Permeability in Crohn’s disease: altered barrier functions in healthy relatives? Gastoenterology, 104, 1848–1851. Hollander, D. (1994). The importance of intestinal permeability in the pathogenesis of Crohn’s disease. In Rachmilewitz, D. (Ed.), Inflammatory Bowel Diseases, Falk Symposium 72. London: Kluwer Academic. (pp. 41–51). Hollander, D. (1999). Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep, 1, 410–416. Hollander, D., Vadheim, C. M., Brettholz, E., et al. (1986). Increased intestinal permeability in Crohn’s patients and their relatives: an etiological factor. Ann Intern Med, 105, 883–885. Hodges, L. S. (2005). Medical Nutrition Therapy for GI Disorders. In: Christie, C. (Ed.), Manual of Medical Nutrition Therapy. Florida Dietetic Association, K2.1–K4.6. Hoffbrand, A. V., Stewart, J. S., & Booth, C. C. (1968). Folate deficiency in Crohn’s disease: Incidence, pathogenesis, and treatment. Br Med J, 2, 71–75. Holt, P. R., Katz, S., & Kirshoff, R. (2005). Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci, 50(11), 2191–2193. Human Genome Project Information. (2007). What is the Human Genome Project? Retrieved November 18 , 2007 from http://www.ornl.gov/sci/techresources/ Human_Genome/home.shtml Humbert, P., Russell, S., & Richardson, H. (2003). Dig, Scribble and Lgl in cell polarity, cell proliferation and cancer. Bioessays, 25, 542–553. Hugot, J. P., Chamaillard, M., Zouali, H., et al. (2001). Association of NOD2 leucinerich repeat variants with susceptibility to Crohn’s disease. Nature, 41, 599–603. Inohara, N., Ogura, Y. & Fontalba, A. (2003). Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn’s disease. J Biol Chem, 278, 5509–5512. Inoue N., Tamura K., & Kinouchi Y. (2002). Lack of common NOD2 variants in Japanese patients with Crohn’s disease. Gastroenterology, 123, 86–91. Jess, T., Riis, L., Jespersgaard, C., et al. (2005). Disease concordance, zygosity, and NOD2/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. Am J Gastroenterol, 100, 2486–2492. Johnston, W. M. (2001). Probiotics Relieve IBS Symptoms Linked to Abnormal Gut Flora. Gastroenterology and Endoscopy News, 38. Jones, D. S. (Ed.). (2005). Textbook of Functional Medicine. Gig Harbor, WA: The Institute for Functional Medicine. Katz, K. D., Hollander, D., Vadheim, C. M. et al. (1989). Intestinal permeability in patients with Crohn’s disease and their healthy relatives. Gastroenterology, 97, 927–931. Kauwell, G. P. (2003). A genomic approach to dietetic practice. Are you ready? Top Clin Nutr, 18, 81–91. Kidd, P. (2003). Th1/Th2 Balance: the hypothesis, its limitations and implications for health and disease. Altern Med Rev, 8, 223–246. Kobayashi, K. S., Chamaillard, M., Ogura, Y., et al. (2005). Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science, 307, 731–734. Kozma, C. (2003). The interface between genomics and nutrition. Top Clin Nutr, 18, 73–80. Kurup, V. P., Barrios, C. S., Raju, R., et al. (2007). Immune response modulation by curcumin in a latex allergy model. Clin Mol Allergy, 5, 1. Lashner, B. A., Shaheen, N. J., Hanauer, S. B., & Kirschner, B. S. (1993). Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol, 88, 356–359. Lee, Y. H., Choi, S. J., Ji, J. D., Seo, H. S., & Song, G. G. (2000). Lipoprotein (a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol, 19, 324–325. Lerebours, E., Gower-Rousseau, C., Merle, V. et al. (2007). Stressful life events as a risk factor for inflammatory bowel disease onset: A population-based case-control study. Am J Gastroenterol, 102, 122–131. Leong, R. W., Armuzzi, A., & Ahmad, T. (2003). NOD2/CARD15 gene polymorphisms and Crohn’s disease in the Chinese population. Aliment Pharmacol Ther, 17, 1465–1470. Lindberg, E., Jarnerot, G., & Huitfeldt, B. (1992). Smoking in Crohn’s disease: effect on localisation and clinical course. Gut, 33, 779–782. Liska, D. J., & Lukaczer, D. (2001). Gut dysfunction and chronic disease: the benefits of applying the 4R GI restoration program. ANSR-Applied Nutrition Science Report, Advanced Nutrition Publication, 1–8. MacDonald, T. T. (2005). Immunity, inflammation, and allergy in the gut. Science, 307, 1920–25. MacPherson, A., Khoo, U. Y., & Forgacs, I. (1996). Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut, 38, 365–375. Mahmood, A., Fitzgerald, A. J., Marchbank T., et al. (2007). Zinc carnosine, a health food supplement that stabilizes small bowel integrity and stimulates gut repair processes. Gut, 56, 168–175. Malin, M., Suomalainen, H., Saxelin, M., & Isolauri, E. (1996). Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab, 40, 137–145. Mathew, C. G., & Lewis, C. M. (2004). Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet, 13, R161–168. May, G. R., Sutherland, L. R., & Meddings, J. B. (1993). Is small intestinal permeability really increased in relatives of patients with Crohn’s disease? Gastroenterology, 104, 1627–1623. Mazmanian, S. K., Liu, C. H., Tzianabos, A. O., & Kasper, D. L. (2005). An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell, 122, 107–118. Mitsushima, M., Sezaki, T., Akahane, R., et al. (2006). Protein kinase A-dependent increase in WAVE2 expression induced by the focal adhesion protein vinexin. Genes to Cells, 11, 281–92. Mittermaier, C., Dejaco, C., Waldhoer, T., et al. (2004). Impact of depressive mood on relapse inpatients with inflammatory bowel disease: a prospective 18-month followup study. Psychosom Med, 66, 79–84. Motil, K. J., & Grand, R. J. (1985). Nutritional management of inflammatory bowel disease. Pediatr Clin North Am, 32, 447–469. Mullin, G. E., Maycon, Z. R., Sampat, A., et al. (1996). Intestinal mucosal lymphokine production in Crohn’s disease has a Th1 profile. Inflamm Bowel Dis, 2, 16–26. Muller, M., & Kersten, S. (2003). Nutrigenomics: goals and strategies. Nature Review/ Genetics, 4, 325–322. Nakamura, H., Sudo, T., Tsuiki, H., et al. (1998). Identification of a novel human homolog of the Drosophila dlg, P-dlg, specifically expressed in the gland tissues and interacting with p55. FEBS Letters, 433, 63–67. Neurath, M. F., Finotto, S., & Glimcher, L. H. (2002). The role of the Th1/Th2 polarization in mucosal immunity. Nat Med, 8, 567–573. Ogura, Y., Bonen, D. K., Inohara, N., et al. (2001). A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature, 411, 603–606. O’Hara, M. A., Kiefer, D., & Farrell, K. (1998). A review of 12 commonly used medicinal herbs. Arch Fam Med, 7, 523–536. OPASI: Office of Portfolio Analysis and Strategic Initiatives. NIH Roadmap for Medical Research. Retrieved December 1, 2007 from http://nihroadmap.nih.gov/buildingblocks Oriishi, T., Sata, M., Toyonaga, A., Sasaki, E., & Tanifawa, K. (1995). Evalution of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A. Gut, 36, 891–896. O’Sullivan, M., & O’Morain, C. (2006). Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenterol, 20, 561–573. Peltekova, V. D., Wintle, R. F., Rubin, L. A., et al. (2004). Functional variants of OCTN cation transporter genes are associated with Crohn’s disease. Nat Genet, 2004, 36, 471–475. Persson, P. G., Ahlbom, A., & Hellers, G. (1990). Inflammatory bowel disease and tobacco smoke–a case-control study. Gut, 31, 1377–1381. Plain, K., & Hotz, J. (1993). Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea–a pilot study. Gastroenterology, 31, 129–134. Ramsay, R. R. (2000). The carnitine acyltransferases: modulators of acyl-CoAdependent reactions. Biochem Soc Trans, 28, 182–186. Rath, H. C., Caesar, I., Roth, M., & Scholmerich, J. (1998). Nutritional deficiencies and complications in chronic inflammatory bowel disease. Med Klin, 93, 6–10 (article in German). Rescigno, M., & Chieppa, M. (2005). Gut-level decisions in peace and war. Nat Med, 11, 254–255. Riley, S. A., Mani, V., Goodman, M. J., et al. (1988). Comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology, 94, 1383–1389. Roediger, W. E., & Nance, S. (1986). Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. British Journal of Experimental, Pathology, 67, 773–782. Schreiber, S., Rosenstiel, P., Albrecht, M., Hampe, J., & Krawczak, M. (2005). Genetics of Crohn’s disease, an archetypal inflammatory barrier disease. Nat Rev Genet, 6, 376–388. Secondulfo, M. de Magistris, L., Fiandra, R., et al. (2001). Intestinal permeability in Crohn’s disease patients and their first degree relatives. Dig Liver Dis, 33, 680–685. Silverberg, M. S., Satsangi, J., & Ahmad, T. (2005). Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol, 19 (supplement A), 5–36. Shapiro, H., Singer, P., Halpern, Z., et al. (2007). Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut, 56(3), 426–435. Sharma, S., Chopra, K., Kulkarni, S. K., et al. (2007). Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol, 147(1), 155–163. Singleton, J. W., Law, D. H., & Kelley, M. L. (1970). National Cooperative Crohn’s Disease Study: Adverse reactions to drugs. Gastroenterology, 77, 870. Somerville, K. W., Logan, R. F., Edmond, M., & Langman, M. J. (1984). Smoking and Crohn’s disease. Br Med J (Clinical Research Edition), 289, 954–956. Sonnenberg, A., McCarty, D.J., & Jacobsen, S. J. (1991). Geographic variation of inflammatory bowel disease within the United States. Gastroenterology, 100, 143–149. Souba, W. W., Klimberg, V. S., & Plumley, D. (1990). The role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection. J Surg Res, 48, 383–391. Stoll, M., Corneliussen, B., Costello, C. M., et al. (2004). Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet, 36, 476–480. Sugimura, M., Kinouchi, Y., Takahashi, S., et al. (2003) CARD15/NOD2 mutational analysis in Japanese patients with Crohn’s disease. Clin Genet, 63, 160–262. Sutton, K. (2007). Considerations for the successful development and launch of personalized nutrigenomic foods. Mutat Res, 622, 117–221. Teahon, K., Roseth, A., Foster, R., & Bjarnason, I. (1997). Faecal calprotectin: a simple sensitive quantitative measure of intestinal inflammation in man [abstract] Gastroenterology, 112(supplement), A1103. Tibble, J. A., Sigthorsson, G., & Bjarnason, I. (1999). High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut, 45, 362–366. Tokuhiro, S. (2003). An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet, 35, 341–348. Vermeire, S., & Rutgeerts, P. (2004). Antibody responses in Crohn’s disease. Gastroenterology, 126, 601–604. Wakabayashi, M. (2003). Interaction of Ip-dlg/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact. J Bio Chem, 278, 21709–21714. Whitney, E. N., Cataldo, C. B., & Rolfes, S. R. (1998). Understanding Normal and Clinical Nutrition. 5th ed. Belmont, CA: West/Wadsworth. Wikipedia. Retrieved November 8, 2007 from http://en.wikipedia.org/wiki/Scaffold_ protein